Efficacy and Safety of Iptacopan in East Asian Patients with IgAN: Final 24-Month Results from the Phase 3 APPLAUSE-IgAN Trial (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #TH-PO0483; Pres time: Oct 22, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; P3 | "Conclusion In East Asian pts with IgAN, iptacopan improved kidney function, as shown by statistically significant and clinically meaningful improvement in total eGFR slope vs PBO and proteinuria reductions over 24 months, with a favorable safety profile. These findings were consistent with the overall APPLAUSE–IgAN population and support the clinical utility of iptacopan in pts from East Asia."
Clinical • P3 data • Glomerulonephritis • IgA Nephropathy • Lupus Nephritis • Nephrology • Renal Disease • CFB
|
|
Hong Zhang; Jonathan Barratt; Vlado Perkovic; Dana V. Rizk; Brad Rovin; Hernan Trimarchi; Bart D. Maes; Manasi Mital Desai; Zenab Attari; Severina Jacinto-Sanders; Annabel Rose Magirr; Lindsay Govan; Ronny Renfurm; Thomas Hach; Naoki Kashihara
|